C3 For Mac

Posted on by admin



C3 For Mac

  1. Mac Nc40
  2. Mac Foundation C3

Macrophage-1 antigen (or integrin αMβ2 or macrophage integrin or Mac-1) is a complement receptor ('CR3') consisting of CD11b (integrin αM) and CD18 (integrin β2).[1]

  • The C3™ client and event server. make up a remote management software suite for DW® VMAX embedded recording solutions. It provides users a powerful and easy-to-use new way to monitor any VMAX device from anywhere. Full-featured yet lightweight, the software delivers simultaneous live views and playback or recorded video.
  • C# (pronounced 'c-sharp') is a great coding language that works across Mac and PC. Programmers use it to build a variety of software applications, especially in the Windows environment.
  • Beige w/ neutral golden undertone for light to medium skin. Light peach w/ golden undertone for light to medium skin. Light golden olive w/ golden undertone for light to medium skin (online only) Shop Now. Peachy golden w/ golden undertone for light to medium skin.
  • Currently, the Mac users can get their hands on two different versions of this utility. The first is a sandboxed version available through the Mac App Store. In this version, you need to provide an authorization when the application runs for the first time to decompress a file.

MAC prefix: BC:C3:42 Vendor name: Panasonic Communications Co., Ltd. MAC range: BC:C3:42:00:00:00 - BC:C3:42:FF:FF:FF Block Size: 16777215 (16.77 M).

The integrin α chain is noncovalently bound to the integrin β chain. It binds to iC3b and can be involved in cellular adhesion, binding to the intercellular adhesion molecule-1 (ICAM-1).[2][3] CR3 causes phagocytosis and destruction of cells opsonized with iC3b. CR3 and CR4 are thought to exhibit overlapping functions; however, the distinct binding sites to iC3b suggests differences in their functions.[4] Additionally, CR3 has been shown to have therapeutic promise.[5][6][7]

Function[edit]

Macrophage-1 antigen (hereafter complement receptor 3 or CR3) (CD11b/CD18) is a human cell surface receptor found on B and T lymphocytes, polymorphonuclear leukocytes (mostly neutrophils), NK cells, and mononuclear phagocytes like macrophages. CR3 is a pattern recognition receptor, capable of recognizing and binding to many molecules found on the surfaces of invading bacteria. CR3 also recognizes iC3b when bound to the surface of foreign cells. iC3b is generated by proteolysis of C3b and binding to the receptor causes phagocytosis and destruction of the foreign cell opsonized with iC3b.

Nc40

CR3 belongs to a family of cell surface receptors known as integrins (because they share this particular β chain, they are referred to as β2-integrins), which are extremely widely distributed throughout nature and which generally are important in cellular adhesion, migration, phagocytosis and other cell-cell interactions in a variety of cells and circumstances.[4]

Upregulation of Mac-1 in the presence of certain factors such as IL-2 may cause a prolongation of the life of the immune cell while the presence of TNF-α induces apoptosis and selective removal of the cell.

A fully activated neutrophil may express on its membrane 200,000 or more CR3 molecules.

Absence of CR3 results in reduced binding and ingestion of Mycobacterium tuberculosis in mice. In human mononuclear phagocytes, phagocytosis of Mycobacterium tuberculosis is mediated in part by human monocyte complement receptors including CR3.[8]

CR3 has also been shown to mediate phagocytosis of the Lyme disease causing bacterium, Borrelia burgdorferi, in the absence of iC3b opsonization.[9]

For

CR3 and CR4[edit]

CR3 and CR4, both members of the β2-integrin family, are generally thought to exhibit overlapping functions in myeloid cells and certain lymphoid populations.[4] CR3 and CR4 have been shown to be 87%[4] homologous via sequence analysis of human cDNA of the α chains; however, the complement receptors bind at distinct sites of iC3b and the intracellular domains differ in length and amino acid sequence, suggesting further differences in their functions.[4] Further, CR3 favors binding to positively charged species, while CR4 binds negatively charged species.[10] It has been shown that both CR3 and CR4 are found in mice and humans.[4] Together, CR3 and CR4 are involved in various functions of the T and B lymphocytes and NK cells. For instance, while both CR3 and CR4 are involved in adhesion, migration and proliferation of B cells, they are involved in enhancing complement-dependent cytotoxicity in NK cells.[4]

CR3 and CR4 for Disease Therapy[edit]

Immunomodulatory therapies often aim for an induced reduction of symptoms in inflammatory disease or supported elimination of malignancies. In vitro and in vivo experiments suggest a response of CR3 and CR4 to enable complement-dependent cell cytotoxicity towards antibody-coated cancer cells.[5][6] Such biological therapeutic targeting is characterized by lowering autoimmune inflammation or enhancing anti-cancer vaccination effects.

Leukadherin-1, a CR3 agonist molecule, has been shown to suppress human innate inflammatory signals. Its anti-inflammatory effect mediation further provides support for its therapeutic promise in animal models of vascular injury.[7]

Synonyms and abbreviations[edit]

  • CR3
  • CD11b/CD18
  • Macrophage 1 antigen (Mac-1)
C3 format string

Mac Nc40

Mac

See also[edit]

Mac Foundation C3

References[edit]

  1. ^Todd R (1996). 'The continuing saga of complement receptor type 3 (CR3)'. J. Clin. Invest. 98 (1): 1–2. doi:10.1172/JCI118752. PMC507390. PMID8690779.
  2. ^Abbas AK, Lichtman AH, Pillai S (2017-03-10). Cellular and Molecular Immunology (Ninth ed.). Philadelphia, PA. ISBN978-0-323-52323-3. OCLC973917896.
  3. ^Ross GD, Vĕtvicka V (May 1993). 'CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions'. Clinical and Experimental Immunology. 92 (2): 181–4. doi:10.1111/j.1365-2249.1993.tb03377.x. PMC1554824. PMID8485905.
  4. ^ abcdefgErdei, Anna; Lukácsi, Szilvia; Mácsik-Valent, Bernadett; Nagy-Baló, Zsuzsa; Kurucz, István; Bajtay, Zsuzsa (2019). 'Non-identical twins: Different faces of CR3 and CR4 in myeloid and lymphoid cells of mice and men'(PDF). Seminars in Cell & Developmental Biology. 85: 110–121. doi:10.1016/j.semcdb.2017.11.025. PMID29174917.
  5. ^ abHu, X.; Wohler, J. E.; Dugger, K. J.; Barnum, S. R. (2010-03-01). '2-Integrins in demyelinating disease: not adhering to the paradigm'. Journal of Leukocyte Biology. 87 (3): 397–403. doi:10.1189/jlb.1009654. ISSN0741-5400. PMC3212424. PMID20007244.
  6. ^ abJoshi, Medha D.; Unger, Wendy J.; Storm, Gert; van Kooyk, Yvette; Mastrobattista, Enrico (2012). 'Targeting tumor antigens to dendritic cells using particulate carriers'. Journal of Controlled Release. 161 (1): 25–37. doi:10.1016/j.jconrel.2012.05.010. PMID22580109.
  7. ^ abBednarczyk, Monika; Stege, Henner; Grabbe, Stephan; Bros, Matthias (2020-02-19). 'β2 Integrins—Multi-Functional Leukocyte Receptors in Health and Disease'. International Journal of Molecular Sciences. 21 (4): 1402. doi:10.3390/ijms21041402. ISSN1422-0067. PMC7073085. PMID32092981.
  8. ^Schlesinger LS, Bellinger-Kawahara CG, Payne NR, Horwitz MA (1990). 'Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3'. J. Immunol. 144 (7): 2771–80. PMID2108212.
  9. ^Hawley KL; Olson Jr. CM. (2012). 'CD14 Cooperates with Complement Receptor 3 to mediate MyD88-Independent Phagocytosis of Borrelia burgdorferi'. Proc Natl Acad Sci USA. 109 (4): 1222–32. Bibcode:2012PNAS..109.1228H. doi:10.1073/pnas.1112078109. PMC3268315. PMID22232682.
  10. ^Vorup-Jensen, Thomas; Jensen, Rasmus Kjeldsen (2018-11-26). 'Structural Immunology of Complement Receptors 3 and 4'. Frontiers in Immunology. 9: 2716. doi:10.3389/fimmu.2018.02716. ISSN1664-3224. PMC6275225. PMID30534123.

Further reading[edit]

  • Wagner C, Hänsch GM, Stegmaier S, Denefleh B, Hug F, Schoels M (April 2001). 'The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function'. Eur. J. Immunol. 31 (4): 1173–80. doi:10.1002/1521-4141(200104)31:4<1173::AID-IMMU1173>3.0.CO;2-9. PMID11298342.
  • Rooyakkers AW, Stokes RW (September 2005). 'Absence of complement receptor 3 results in reduced binding and ingestion of Mycobacterium tuberculosis but has no significant effect on the induction of reactive oxygen and nitrogen intermediates or on the survival of the bacteria in resident and interferon-gamma activated macrophages'. Microb. Pathog. 39 (3): 57–67. doi:10.1016/j.micpath.2005.05.001. hdl:2429/15708. PMID16084683.

External links[edit]

  • Macrophage-1+antigen at the US National Library of Medicine Medical Subject Headings (MeSH)
Retrieved from 'https://en.wikipedia.org/w/index.php?title=Macrophage-1_antigen&oldid=984392642'